Metabolic and Dietary Factors in Acne Vulgaris and Evaluation of the Acne Vulgaris Treatment with Oral Contraceptive-Based Therapies in Young Adult Women.
acne
acne vulgaris
cholesterol
contraception
dairy
glucose
insulin
sweets
treatment
triglycerides
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
20 Mar 2023
20 Mar 2023
Historique:
received:
26
11
2022
revised:
05
03
2023
accepted:
19
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
The etiopathogenesis of acne is complex, as several endo- and exogenous factors that affect the sebaceous-hair unit are involved in the development of acne lesions. The main aim of the study was to evaluate selected metabolic parameters before treatment. Another goal of the study was to determine the correlation between selected metabolic and dietary parameters and the severity of acne before treatment. The third objective was to assess the severity of acne before and after treatment, considering the type of treatment used. The final objective was to assess the relationship between the difference in acne severity before and after treatment, considering the type of treatment used and factors of dairy or sweets intake. 168 women participated in the study. The patients belonged to two groups: the study group (99 patients with acne vulgaris) and the control group (69 patients without skin lesions). The study group was divided into subgroups according to the treatment used: contraceptive preparation, contraceptive preparation and cyproterone acetate, and contraceptive preparation and isotretinoin preparation. We found that LDL levels and consumption of sweets correlated with acne severity. The mainstay of acne treatment is contraceptive treatment (ethinylestradiol and drospirenone). The effectiveness of the three contraceptive-based treatments was confirmed by observing the severity of acne. There were no significant correlations between the difference in acne severity before and after treatment with the three treatments and factors of dairy or sweet consumption.
Identifiants
pubmed: 36986218
pii: nu15061488
doi: 10.3390/nu15061488
pmc: PMC10057923
pii:
doi:
Substances chimiques
Contraceptives, Oral
0
Ethinyl Estradiol
423D2T571U
Cyproterone Acetate
4KM2BN5JHF
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Cells. 2021 Jun 09;10(6):
pubmed: 34207527
Int J Dermatol. 2022 Aug;61(8):930-934
pubmed: 34423427
Best Pract Res Clin Obstet Gynaecol. 2016 Nov;37:98-118
pubmed: 27387253
Acta Derm Venereol. 2013 Nov;93(6):644-9
pubmed: 23975508
Sci Rep. 2020 Apr 1;10(1):5754
pubmed: 32238884
Dermatology. 2015;230(1):34-9
pubmed: 25413494
Int J Dermatol. 2021 Jun;60(6):672-685
pubmed: 33462816
Br J Dermatol. 2008 Sep;159(4):990-1
pubmed: 18652583
Am J Clin Dermatol. 2021 Jan;22(1):55-65
pubmed: 32748305
J Am Acad Dermatol. 2022 Mar;86(3):532
pubmed: 34999151
J Cosmet Dermatol. 2020 Aug;19(8):2109-2113
pubmed: 31840382
Nat Rev Dis Primers. 2015 Sep 17;1:15029
pubmed: 27189872
J Clin Med. 2022 Jul 01;11(13):
pubmed: 35807109
J Eur Acad Dermatol Venereol. 2017 Mar;31(3):530-535
pubmed: 27422392
J Drugs Dermatol. 2014 Apr;13(4):428-35
pubmed: 24719062
Am Fam Physician. 2017 Jun 1;95(11):740-741
pubmed: 28671431
Ginekol Pol. 2012 Mar;83(3):229-32
pubmed: 22568201
Dermatology. 2013;226(2):167-71
pubmed: 23689531
Int J Dermatol. 2015 Jun;54(6):662-6
pubmed: 24961925
Cochrane Database Syst Rev. 2012 Jul 11;(7):CD004425
pubmed: 22786490
Nestle Nutr Workshop Ser Pediatr Program. 2011;67:131-45
pubmed: 21335995
J Clin Endocrinol Metab. 2004 Feb;89(2):453-62
pubmed: 14764747
Br J Dermatol. 1984 Jul;111(1):83-92
pubmed: 6234917
J Eur Acad Dermatol Venereol. 2017 Sep;31 Suppl 5:8-12
pubmed: 28805938
Postepy Dermatol Alergol. 2015 Aug;32(4):281-5
pubmed: 26366152
Arch Dermatol. 2002 Dec;138(12):1584-90
pubmed: 12472346
JAMA Dermatol. 2020 Aug 1;156(8):854-862
pubmed: 32520303
Biochem J. 1988 Apr 1;251(1):95-103
pubmed: 3390164
Cochrane Database Syst Rev. 2018 Nov 24;11:CD009435
pubmed: 30484286
J Am Acad Dermatol. 2016 Jul;75(1):155-62
pubmed: 27061046
G Ital Dermatol Venereol. 2016 Aug;151(4):353-7
pubmed: 26373866
BMC Med Genomics. 2021 Apr 13;14(1):103
pubmed: 33849530
Eur J Endocrinol. 2017 Feb;176(2):R53-R65
pubmed: 27601016
J Clin Med. 2022 Oct 25;11(21):
pubmed: 36362497
Pediatr Dermatol. 1991 Sep;8(3):185-8
pubmed: 1836060
J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e414-9
pubmed: 22924863
J Clin Endocrinol Metab. 1993 May;76(5):1111-4
pubmed: 8496299
Br J Dermatol. 2022 Apr;186(4):673-683
pubmed: 34758111
J Am Acad Dermatol. 2005 Feb;52(2):207-14
pubmed: 15692464
J Eur Acad Dermatol Venereol. 2013 Feb;27(2):254-7
pubmed: 23457723
J Am Acad Dermatol. 2016 May;74(5):945-73.e33
pubmed: 26897386
Am Fam Physician. 2019 Oct 15;100(8):475-484
pubmed: 31613567
Cureus. 2021 Dec 22;13(12):e20593
pubmed: 35103169
Arch Dermatol. 2005 Mar;141(3):333-8
pubmed: 15781674